Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update

Med J Aust. 2014 Mar 17;200(5):267-70. doi: 10.5694/mja13.11331.

Abstract

• Guidelines reflecting contemporary clinical practice in the management of Buruli ulcer (Mycobacterium ulcerans infection) in Australia were published in 2007. • Management has continued to evolve, as new evidence has become available from randomised trials, case series and increasing clinical experience with oral antibiotic therapy. • Therefore, guidelines on the diagnosis, treatment and prevention of Buruli ulcer in Australia have been updated. They include guidance on the new role of antibiotics as first-line therapy; the shortened duration of antibiotic treatment and the use of all-oral antibiotic regimens; the continued importance, timing and role of surgery; the recognition and management of paradoxical reactions during antibiotic treatment; and updates on the prevention of disease.

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use
  • Australia
  • Buruli Ulcer / drug therapy*
  • Buruli Ulcer / prevention & control
  • Buruli Ulcer / surgery
  • Debridement
  • Drug Therapy, Combination
  • Hot Temperature / therapeutic use
  • Humans
  • Mycobacterium ulcerans
  • Practice Guidelines as Topic
  • Rifampin / administration & dosage
  • Rifampin / therapeutic use
  • Streptomycin / administration & dosage
  • Streptomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Rifampin
  • Streptomycin